Drug intelligence / Profile preview

lysozyme

Development stage
Phase 4
Lead developer
Santen Pharmaceutical
Modality
Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration
Oral
01

Overview

Lysozyme is a naturally occurring antimicrobial enzyme and protein found in various body fluids such as tears, saliva, mucus, and sweat. It plays a key role in the innate immune system by hydrolyzing glycosidic bonds in peptidoglycans of bacterial cell walls—especially those of Gram-positive bacteria—leading to cell lysis and death[1][3][4]. Lysozyme also exhibits antiviral and antifungal activities and has immunomodulatory effects by influencing inflammatory cytokine production[2][6]. Clinically, it is used as an anti-inflammatory agent for conditions like oral ulcers, throat infections, chronic sinusitis, minor bleeding during surgery, phlegm production disorders (e.g., chronic bronchitis), gastrointestinal disorders in infants (including diarrhea), herpes simplex/zoster co-adjuvant therapy (in some countries), and supportive care for immune function[4][5][7][8]. It is available as tablets or topical preparations; typical adult doses are 90 mg per dose two to three times daily or higher depending on indication[2][5]. Lysozyme has been approved for medical use mainly in France, Italy, Latvia; elsewhere it may be considered investigational or used as a supplement[8].

Brand names
Lysozyme
Other names
溶菌酶muramidase
02

Targets

PGN (Peptidoglycan)

Beyond the preview

Go deeper on lysozyme.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lysozyme.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call